Table 2

Summary of odds to be in remission/LDA comparing patients with obesity versus non-obese

Univariable modelMultivariable model*
OR (95% CI)POR (95% CI)P
 DAPSA-REM0.32 (0.16, 0.62)0.0010.39 (0.19, 0.80)0.009
 VLDA0.23 (0.10, 0.55)0.0010.31 (0.13, 0.77)0.011
 Remission by patients’ opinion0.869 (0.504, 1.497)0.613
 DAPSA-LDA0.448 (0.263, 0.762)0.0030.728 (0.446, 1.187)0.203
 MDA0.50 (0.31, 0.78)0.0020.61 (0.38, 0.99)0.045
 LDA by patients’ opinion0.80 (0.51, 1.26)0.333
  • Bold: variables statistically significantly associated with remission/ LDA of interest.

  • *List of adjustment variables considered were age, sex, years of schooling, duration of PsA, current use of cDMARDs, current use of bDMARDs and other comorbidities in FCI. Variables adjusted in each multivariable model were chosen from those with significant p<0.1 in univariable model as detailed in online supplemental tables 4–8.

  • bDMARDs, biological disease modifying anti-rheumatic drugs; csDMARDs, conventional synthetic disease modifying anti-rheumatic drugs; DAPSA, Disease Activity in PSoriatic Arthritis; FCI, Functional Comorbidity Index; LDA, low disease activity status; REM, remission; VLDA, very low disease activity; vs, versus.